Nutrition, Metabolism & Cardiovascular Diseases
Volume 20, Issue 1 , Pages 7-14, January 2010

Correlates of quality of life in adults with type 1 diabetes treated with continuous subcutaneous insulin injection

  • M. Franciosi

      Affiliations

    • Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro (CH), Italy
    • On behalf of the EQuality1 Study Group.
  • ,
  • A. Maione

      Affiliations

    • Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro (CH), Italy
    • On behalf of the EQuality1 Study Group.
  • ,
  • B. Pomili

      Affiliations

    • Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro (CH), Italy
    • On behalf of the EQuality1 Study Group.
  • ,
  • R. Amoretti

      Affiliations

    • Diabetes Unit, Azienda Ospedaliera S. Giovanni Addolorata, Roma, Italy
    • On behalf of the EQuality1 Study Group.
  • ,
  • E. Busetto

      Affiliations

    • Fondazione Medtronic Italia, Sesto San Giovanni (MI), Italy
    • On behalf of the EQuality1 Study Group.
  • ,
  • F. Capani

      Affiliations

    • Department of Medicine and Ageing, University “G. D'Annunzio”, Chieti, Italy
    • OnLine University “Leonardo da Vinci” – Torrevecchia Teatina (CH), Italy
    • On behalf of the EQuality1 Study Group.
  • ,
  • D. Bruttomesso

      Affiliations

    • Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
    • On behalf of the EQuality1 Study Group.
  • ,
  • P. Di Bartolo

      Affiliations

    • Diabetes Unit, AUSL Provincia di Ravenna, Ravenna, Italy
    • On behalf of the EQuality1 Study Group.
  • ,
  • A. Girelli

      Affiliations

    • Diabetes Unit, Spedali Civili di Brescia, Brescia, Italy
    • On behalf of the EQuality1 Study Group.
  • ,
  • F. Leonetti

      Affiliations

    • Department of Clinical Sciences, La Sapienza University, Roma, Italy
    • On behalf of the EQuality1 Study Group.
  • ,
  • L. Morviducci

      Affiliations

    • Diabetes Unit, San Camillo Hospital, Roma, Italy
    • On behalf of the EQuality1 Study Group.
  • ,
  • P. Ponzi

      Affiliations

    • Fondazione Medtronic Italia, Sesto San Giovanni (MI), Italy
    • On behalf of the EQuality1 Study Group.
  • ,
  • E. Vitacolonna

      Affiliations

    • Department of Medicine and Ageing, University “G. D'Annunzio”, Chieti, Italy
    • OnLine University “Leonardo da Vinci” – Torrevecchia Teatina (CH), Italy
    • On behalf of the EQuality1 Study Group.
  • ,
  • A. Nicolucci

      Affiliations

    • Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro (CH), Italy
    • Corresponding Author InformationCorresponding author. Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale, 8/A - 66030 Santa Maria Imbaro (Chieti), Italy. Tel.: +39 0872570260; fax: +39 0872570263.
    • On behalf of the EQuality1 Study Group.

Received 18 November 2008; received in revised form 20 February 2009; accepted 20 February 2009. published online 14 September 2009.

Abstract 

Background and aims

Aim of this study was to identify subgroups of adults with Type 1 Diabetes Mellitus (T1DM) treated with Continuous Subcutaneous Insulin Infusion (CSII) at higher risk of poor quality of life (QoL).

A sample of consecutive patients completed the Diabetes Specific Quality of Life Scale (DSQOLS), investigating the daily burden and restrictions related to diabetes. Lower DSQOLS scores indicate worse QoL perception.

Methods and results

The main results were obtained by using a regression-tree technique (RECursive Partitioning and AMalgamation – RECPAM) and multivariate logistic regression.

Overall, 472 patients aged between 18 and 55 years were recruited by 43 Italian centers. RECPAM analysis led to the identification of 5 classes characterized by a marked difference in QoL. Male patients not reporting episodes of ketoacidosis and using CSII for >2 years had the lowest likelihood of scoring in the lower tertile of the DSQOLS summary score, and thus represented the reference category.

Patients who reported ≥1 ketoacidosis episodes (OR = 5.4; 95% CI 2.4–12.1) and female patients with a duration of diabetes of <10 years (OR = 5.9; 95% CI 2.6–13.5) had the highest likelihood of reporting poor QoL, while females with longer diabetes duration (OR = 2.4; 95% CI 1.3–4.7) and males treated with CSII for ≤2 years (OR = 2.2; 95% CI 1.1–4.6) showed a two-fold risk of poor QoL. Patient age, diabetic complications and civil status were globally predictive variables associated with poor QoL.

Conclusion

We identified subgroups of T1DM individuals treated with CSII showing a major impairment in QoL. Specific strategies are needed to help the patient cope with this therapeutic modality, especially during the initial phase of treatment.

Keywords: Type 1 Diabetes, CSII, Quality of life, RECPAM analysis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Parts of this study have been presented at the 44th EASD Annual Meeting Roma, Italy – September 7–11 2008.

PII: S0939-4753(09)00043-X

doi:10.1016/j.numecd.2009.02.012

Nutrition, Metabolism & Cardiovascular Diseases
Volume 20, Issue 1 , Pages 7-14, January 2010